ACTIV4a

28 posts

ACTIV4a banner
ACTIV4a

ACTIV4a

@ACTIV4a

Official account of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Acute Inpatient Anti-Thrombotic Study (ACTIV-4a)

Katılım Aralık 2020
26 Takip Edilen235 Takipçiler
ACTIV4a retweetledi
Dr. Jeffrey Berger
Dr. Jeffrey Berger@PlateletDoc·
>95% confidence in futility in non-critically #Covid_19 - @ACTIV4a still enrolling P2Y12 in critically ill patients - generating data at warp speed thanks to @NIHFunding @nih_nhlbi
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦@DrMarthaGulati

#AHA21 #LBCT P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A 🩸thrombosis/inflam in #COVID 🩸RCT of P2Yy12, non-critical pt: 562 pts 🩸Stopped for futility; 40% women; Ticag used in 63% 🩸 No benefit of P2Yy12 in non-critical pts @AHAMeetings

English
0
6
14
0
ACTIV4a retweetledi
NEJM
NEJM@NEJM·
In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. nej.md/3jrrxJx #IDTwitter
NEJM tweet media
English
3
115
228
0
ACTIV4a retweetledi
Ryan Zarychanski
Ryan Zarychanski@RZarychanski·
The final presentation timed with a public report. Come find out how the trial was done & what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19. @ATTACC_COVID @remap_cap @ACTIV4a @UM_RadyFHS @UHN @CCCTG_ @canvector @ASH_hematology @JustinTrudeau
Critical Care Reviews@CritCareReviews

Big night tomorrow night! Free livestream from 20:30 UTC criticalcarereviews.com Supported by @MyIntensiveCare

English
0
17
42
0
ACTIV4a retweetledi
remap-cap
remap-cap@remap_cap·
For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8
English
2
70
155
0
ACTIV4a retweetledi
Ryan Zarychanski
Ryan Zarychanski@RZarychanski·
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. medrxiv.org/content/10.110…
English
5
70
142
0
ACTIV4a retweetledi
Professor Beverley Hunt OBE (also on BlueSky)
Professor Beverley Hunt OBE (also on BlueSky)@bhwords·
In this free access @bmj_latest editorial we discuss - the changing views & practice of thromboprophylaxis in hospitalised patients with COVI-19 through the pandemic - the recent RCT interim evidence from @remap_cap @ATTACC_COVID & @ACTIV4a as to what is the best dose of LMWH
Claire McLintock@doctormclintock

Honoured to have co-written this @BMJ editorial dx.doi.org/10.1136/bmj.n4… @bhwords @PaulaErich MertDumantepe #thromboprophylaxs for #COVID19 important comment on current knowledge - all members of @thrombosisday steering group.

English
1
42
73
0
ACTIV4a retweetledi
University of Pittsburgh
University of Pittsburgh@PittTweet·
Early results of a worldwide trial, coordinated in part by researchers at Pitt, found that full doses of heparin, a blood thinner, were not only safe but also reduced the need for vital organ support, such as ventilation for COVID-19 patients. More here: bit.ly/3oemMDy
University of Pittsburgh tweet media
English
0
15
32
0

Keşfet

@NIHFunding @AHAMeetings @UofT_DoM @ecgoligher @remap_cap @NEJM @UM_RadyFHS @UHN